|1.||Fidler, Isaiah J: 1 article (07/2006)|
|2.||Baker, Cheryl H: 1 article (07/2006)|
|3.||Trevino, Jose G: 1 article (07/2006)|
|4.||Caron, Alexis: 1 article (07/2006)|
|5.||Nesbit, Mark: 1 article (07/2006)|
|6.||Zhang, Fahao: 1 article (07/2006)|
|7.||Gallick, Gary E: 1 article (07/2006)|
|8.||Summy, Justin M: 1 article (07/2006)|
|1.||Pancreatic Neoplasms (Pancreatic Cancer)
07/01/2006 - "Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice."
07/01/2006 - "We determined whether oral administration of GN963, alone or in combination with gemcitabine produces therapy against L3.6pl human pancreatic cancer cells growing orthotopically in nude mice. "
07/01/2006 - "Administration of GN963 inhibited PDGFR phosphorylation in both tumor and tumor-associated endothelial cells, decreased Src and Akt kinase activity in tumor cells, decreased microvessel density, and decreased tumor cell proliferation, while increasing apoptosis of tumor and tumor-associated endothelial cells. "
07/01/2006 - "In contrast, treatment with GN963 (100 mg/kg) or GN963 plus gemcitabine produced a 52% and 81% decrease in tumor volume, respectively. "
|3.||Neoplasm Metastasis (Metastasis)